Literature DB >> 6214497

In vitro effect of (3-amino-1-hydroxypropylidene)-1,1-bisphosphonic acid (APD) on the function of mononuclear phagocytes in lymphocyte proliferation.

E de Vries, J P van der Weij, C J van der Veen, H C van Paassen, M J Jager, H P Sleeboom, O L Bijvoet, A Cats.   

Abstract

The effect of (3-amino-1-hydroxypropylidene)-1,1-bisphosphonic acid (APD) on pokeweed mitogen-stimulated and non-stimulated cultures of peripheral blood mononuclear cells was studied in vitro. It is shown that APD can inhibit partially lymphocyte proliferation when added to a suspension of mononuclear cells before stimulation, but that lymphocyte proliferation can continue when the drug is withdrawn. In contrast; when APD is added to the cell suspension together with the mitogen, lymphocyte proliferation remains low even when the drug is withdrawn. Addition of different concentration of mononuclear phagocytes (MNP) to non-adherent cells, followed by stimulation in the presence of APD, indicates that APD acts on MNP function preferentially and does not affect lymphocyte proliferation.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6214497      PMCID: PMC1555519     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  17 in total

1.  Human monocyte and macrophage modulation of lymphocyte proliferation.

Authors:  J J Rinehart; M Orser; M E Kaplan
Journal:  Cell Immunol       Date:  1979-04       Impact factor: 4.868

2.  The role of monocytes in human lymphocyte activation by mitogens.

Authors:  J E de Vries; A P Caviles; W S Bont; J Mendelsohn
Journal:  J Immunol       Date:  1979-03       Impact factor: 5.422

3.  Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).

Authors:  W B Frijlink; O L Bijvoet; J te Velde; G Heynen
Journal:  Lancet       Date:  1979-04-14       Impact factor: 79.321

4.  Studies on the regulation of lymphocyte reactivity by normal and activated macrophages.

Authors:  E J Wing; J S Remington
Journal:  Cell Immunol       Date:  1977-04       Impact factor: 4.868

5.  Lymphocyte activation. I. Response of T and B lymphocytes to phytomitogens.

Authors:  G Janossy; M F Greaves
Journal:  Clin Exp Immunol       Date:  1971-10       Impact factor: 4.330

6.  Pretreatment of plastic Petri dishes with fetal calf serum. A simple method for macrophage isolation.

Authors:  K Kumagai; K Itoh; S Hinuma; M Tada
Journal:  J Immunol Methods       Date:  1979       Impact factor: 2.303

7.  Monocyte dependence of pokeweed mitogen-induced differentiation of immunoglobulin-secreting cells from human peripheral blood mononuclear cells.

Authors:  S A Rosenberg; P E Lipsky
Journal:  J Immunol       Date:  1979-03       Impact factor: 5.422

8.  Diphosphonates inhibit bone resorption by macrophages in vitro.

Authors:  T J Chambers
Journal:  J Pathol       Date:  1980-11       Impact factor: 7.996

9.  Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).

Authors:  F J van Breukelen; O L Bijvoet; A T van Oosterom
Journal:  Lancet       Date:  1979-04-14       Impact factor: 79.321

10.  Regulation of Fc fragment-induced murine spleen cell proliferation.

Authors:  E L Morgan; W O Weigle
Journal:  J Exp Med       Date:  1980-01-01       Impact factor: 14.307

View more
  9 in total

1.  Studies on the chronic phase of adjuvant arthritis: effect of SR 41319, a new diphosphonate.

Authors:  A Barbier; J C Breliére; B Remandet; R Roncucci
Journal:  Ann Rheum Dis       Date:  1986-01       Impact factor: 19.103

Review 2.  Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  A Fitton; D McTavish
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

3.  Effect of dichloromethylene diphosphonate (Cl2MDP) on immune function in breast cancer patients with bone metastases.

Authors:  R Markkula; H Repo; M Leirisalo; C Blomqvist; I Elomaa
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

4.  Comparative study of etidronate and SR 41319, a new diphosphonate, on passive cutaneous anaphylaxis and phospholipase A2 activity.

Authors:  A Barbier; J C Breliere; R Paul; R Roncucci
Journal:  Agents Actions       Date:  1985-03

5.  Inhibition of growth and metastasis of syngeneic transplantable tumours by an aromatic retinoic acid analogue. 2. T cell dependence of retinoid effects in vivo.

Authors:  S A Eccles; H P Purvies; S C Barnett; P Alexander
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

6.  The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins.

Authors:  R E Hewitt; A Lissina; A E Green; E S Slay; D A Price; A K Sewell
Journal:  Clin Exp Immunol       Date:  2005-01       Impact factor: 4.330

7.  Intravenous pamidronate for refractory rheumatoid arthritis.

Authors:  Mansour Salesi; Peyman Mottaghi; Mansour Karimifar; Ziba Farajzadegan
Journal:  J Res Med Sci       Date:  2012-05       Impact factor: 1.852

Review 8.  Interventions for preventing bone disease in kidney transplant recipients.

Authors:  Suetonia C Palmer; Edmund Ym Chung; David O McGregor; Friederike Bachmann; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2019-10-22

9.  Sternocostoclavicular Hyperostosis: Positive Clinical and Radiological Response on Pamidronate.

Authors:  Anne T Leerling; Ana Navas Cañete; Ashna I E Ramautar; Natasha M Appelman-Dijkstra; Elizabeth M Winter
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-18       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.